Evidence map›Paper›PMID 35295232›Full record

ReviewERJ open research2022

Mortality and survival in idiopathic pulmonary fibrosis: a systematic review and meta-analysis.

Qiang Zheng, Ingrid A Cox, Julie A Campbell, Qing Xia, Petr Otahal, Barbara de Graaff, Tamera J Corte, Alan K Y Teoh, E Haydn Walters, Andrew J Palmer

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in ERJ open research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 75 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
75citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

75 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Clinical care in interstitial lung disease: a critical appraisal of clinical guidance documents.European respiratory review : an official journal of the European Respiratory Society · 2025
    Pooled it
  3. Pooled it
  4. Article
  5. Review
  6. Article
  7. MCT4 mediates hypoxia-induced extracellular lactate release from IPF fibroblasts.American journal of respiratory cell and molecular biology · 2026
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Review
  18. Observational
  19. Article
  20. Article

15 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Qiang ZhengMenzies Institute for Medical Research, University of Tasmania, Hobart, Australia.ORCID https://orcid.org/0000-0002-7020-3239
Ingrid A CoxMenzies Institute for Medical Research, University of Tasmania, Hobart, Australia.ORCID https://orcid.org/0000-0001-5130-4088
Julie A CampbellMenzies Institute for Medical Research, University of Tasmania, Hobart, Australia.
Qing XiaMenzies Institute for Medical Research, University of Tasmania, Hobart, Australia.
Petr OtahalMenzies Institute for Medical Research, University of Tasmania, Hobart, Australia.
Barbara de GraaffMenzies Institute for Medical Research, University of Tasmania, Hobart, Australia.
Tamera J CorteNHMRC Centre of Research Excellence for Pulmonary Fibrosis, Camperdown, Australia.
Alan K Y TeohNHMRC Centre of Research Excellence for Pulmonary Fibrosis, Camperdown, Australia.
E Haydn WaltersSchool of Medicine, University of Tasmania, Hobart, Australia.
Andrew J PalmerMenzies Institute for Medical Research, University of Tasmania, Hobart, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: There are substantial advances in diagnosis and treatment for idiopathic pulmonary fibrosis (IPF), but without much evidence available on recent mortality and survival trends. Methods: A narrative synthesis approach was used to investigate the mortality trends, then meta-analyses for survival trends were carried out based on various time periods. Results: Six studies reported the mortality data for IPF in 22 countries, and 62 studies (covering 63 307 patients from 20 countries) reported survival data for IPF. Age-standardised mortality for IPF varied from ∼0.5 to ∼12 per 100 000 population per year after year 2000. There were increased mortality trends for IPF in Australia, Brazil, Belgium, Canada, Czech Republic, Finland, France, Germany, Hungary, Italy, Lithuania, the Netherlands, Poland, Portugal, Spain, Sweden and UK, while Austria, Croatia, Denmark, Romania and the USA showed decreased mortality trends. The overall 3-year and 5-year cumulative survival rates (CSRs) were 61.8% (95% CI 58.7-64.9; I Discussion: IPF is a diagnosis associated with high mortality. There was no observed increasing survival trend for patients with IPF before year 2010, with then a switch to an improvement, which is probably multifactorial.

Identifiers

PMID35295232
PMCPMC8918939

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.